Challenges in the adoption of new pharmacotherapeutics for addiction to alcohol and other drugs

Pharmacology and Therapeutics

Volumn 108, Issue 1 SPEC. ISS., 2005, Pages 119-128

  Saxon, Andrew J ^a,b   McCarty, Dennis ^c  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Adoption of innovations; Buprenorphine; Pharmacotherapy

Indexed keywords

BUPRENORPHINE; CLONIDINE; DISULFIRAM; METHADONE; NALOXONE;

ADDICTION; ALCOHOLISM; COST BENEFIT ANALYSIS; DRUG ABUSE; DRUG DEPENDENCE; HEALTH CARE COST; HUMAN; LIVER TOXICITY; PHYSICIAN; PREVALENCE; PRIORITY JOURNAL; REVIEW; SUBSTANCE ABUSE; TEACHER; TRAINING;

EID: 25444517718     PISSN: 01637258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2005.06.014     Document Type: Review

References (77)

1. L. Amass, W. Ling, T.E. Freese, C. Reiber, J.J. Annon, and A.J. Cohen Bringing buprenorphine-naloxone detoxification to community treatment providers: the NIDA Clinical Trials Network field experience Am J Addict 13 Suppl. 1 2004 S42 S66
2. M. Auriacombe, M. Fatseas, J. Dubernet, J.P. Daulouede, and J. Tignol French field experience with buprenorphine Am J Addict 13 Suppl. 1 2004 S17 S28
3. P.G. Barnett The cost-effectiveness of methadone maintenance as a health care intervention Addiction 94 1999 479 488
4. P.G. Barnett, G.S. Zaric, and M.L. Brandeau The cost-effectiveness of buprenorphine maintenance therapy for opiate addiction in the United States Addiction 96 2001 1267 1278
5. J. Bell, R. Mattick, A. Hay, J. Chan, and W. Hall Methadone maintenance and drug-related crime J Subst Abuse 9 1997 15 25
6. J. Beney, L.A. Bero, and C. Bond Expanding the roles of outpatient pharmacists: effects on health services utilisation, costs, and patient outcomes Cochrane Database Syst Rev 2 2000 10.1002/14651858.CD000336
7. M.S. Boghdadi, and R.J. Henning Cocaine: pathophysiology and clinical toxicology Heart Lung 26 1997 466 483 (quiz 484-5)
8. G. Brigham, J.M. Harrer, T. Winhusen, A. Pelt, and L. Amass Integrating buprenorphine-naloxone tablet treatment for short-term withdrawal from opioids into a residential integrated addiction and mental health service College on Problems of Drug Dependence 66th Annual Meeting, San Juan, Puerto Rico 2004
9. R.K. Brooner, V.L. King, M. Kidorf, C.W. Schmidt Jr., and G.E. Bigelow Psychiatric and substance use comorbidity among treatment-seeking opioid abusers Arch Gen Psychiatry 54 1997 71 80
10. T.C. Buchmueller, and S.H. Zuvekas Drug use, drug abuse, and labour market outcomes Health Econ 7 1998 229 245
11. K.M. Carroll, B.J. Rounsaville, and K.J. Bryant Alcoholism in treatment-seeking cocaine abusers: clinical and prognostic significance J Stud Alcohol 54 1993 199 208
12. K.M. Carroll, L.R. Fenton, S.A. Ball, C. Nich, T.L. Frankforter, and J. Shi Efficacy of disulfiram and cognitive behavior therapy in cocaine-dependent outpatients: a randomized placebo-controlled trial Arch Gen Psychiatry 61 2004 264 272
13. C. Chaix-Couturier, I. Durand-Zaleski, D. Jolly, and P. Durieux Effects of financial incentives on medical practice: results from a systematic review of the literature and methodological issues Int J Qual Health Care 12 2000 133 142
14. N.C. Clark, N. Lintzeris, and P.J. Muhleisen Severe opiate withdrawal in a heroin user precipitated by a massive buprenorphine dose Med J Aust 176 2002 166 167
15. E.D. Collins, T. Horton, K. Reinke, E.V. Nunes, and L. Amass Buprenorphine-naloxone tablet treatment for brief withdrawal from opioids: initial experience in a therapeutic community College on Problems of Drug Dependence 66th Annual Meeting, San Juan, Puerto Rico 2004
16. J.R. Cooper Including narcotic addiction treatment in an office-based practice JAMA 273 1995 1619 1620
17. P. Crits-Christoph, L. Siqueland, J. Blaine, A. Frank, L. Luborsky, and L.S. Onken Psychosocial treatments for cocaine dependence: National Institute On Drug Abuse Collaborative Cocaine Treatment Study (see comment) Arch Gen Psychiatry 56 1999 493 502
18. J.C. Cross, B.D. Johnson, W.R. Davis, and H.J. Liberty Supporting the habit: income generation activities of frequent crack users compared with frequent users of other hard drugs Drug Alcohol Depend 64 2001 191 201
19. D. Davis, M.A. O'Brien, N. Freemantle, F.M. Wolf, P. Mazmanian, and A. Taylor-Vaisey Impact of formal continuing medical education: do conferences, workshops, rounds, and other traditional continuing education activities change physician behavior or health care outcomes? JAMA 282 1999 867 874
20. P.M. Flynn, P.L. Kristiansen, J.V. Porto, and R.L. Hubbard Costs and benefits of treatment for cocaine addiction in DATOS Drug Alcohol Depend 57 1999 167 174
21. M.T. French, J.A. Mauskopf, J.L. Teague, and E.J. Roland Estimating the dollar value of health outcomes from drug-abuse interventions Med Care 34 1996 890 910
22. M.T. French, K.A. McGeary, D.D. Chitwood, and C.B. McCoy Chronic illicit drug use, health services utilization and the cost of medical care Soc Sci Med 50 2000 1703 1713
23. A. Fugelstad, G. Agren, and A. Romelsjo Changes in mortality, arrests, and hospitalizations in nonvoluntarily treated heroin addicts in relation to methadone treatment Subst Use Misuse 33 1998 2803 2817
24. M. Gossop, J. Marsden, D. Stewart, and A. Rolfe Reductions in acquisitive crime and drug use after treatment of addiction problems: 1-year follow-up outcomes Drug Alcohol Depend 58 2000 165 172
25. I. Grattagliano, P. Portincasa, V.O. Palmieri, and G. Palasciano Overview on the mechanisms of drug-induced liver cell death Ann Hepatol 1 2002 162 168
26. R. Grol, and J. Grimshaw From best evidence to best practice: effective implementation of change in patients' care Lancet 362 2003 1225 1230
27. R. Grol, and M. Wensing What drives change? Barriers to and incentives for achieving evidence-based practice Med J Aust 180 2004 15
28. L.M. Gunne, and L. Gronbladh The Swedish methadone maintenance program: a controlled study Drug Alcohol Depend 7 1981 249 256
29. H.J. Harwood, D. Fountain, and G. Fountain Economic cost of alcohol and drug abuse in the united states. 1992: a report (see comment) Addiction 94 1999 631 635
30. H.W. Haverkos, and W.R. Lange From the alcohol, drug abuse, and mental health administration. Serious infections other than human immunodeficiency virus among intravenous drug abusers J Infect Dis 161 1990 894 902
31. S.H. Heil, G.J. Badger, and S.T. Higgins Alcohol dependence among cocaine-dependent outpatients: demographics, drug use, treatment outcome and other characteristics J Stud Alcohol 62 2001 14 22
32. J.E. Hollander The management of cocaine-associated myocardial ischemia N Engl J Med 333 1995 1267 1272
33. Y.I. Hser, V. Hoffman, C.E. Grella, and M.D. Anglin A 33-year follow-up of narcotics addicts Arch Gen Psychiatry 58 2001 503 508
34. R.L. Hubbard, S.G. Craddock, and J. Anderson Overview of 5-year follow up outcomes in the drug abuse treatment outcome studies (datos) J Subst Abuse Treat 25 2003 125 134
35. Institute of Medicine Bridging the Gap Between Practice and Research: Forging Partnerships with Community-Based Drug and Alcohol Treatment 1998 National Academy Press Washington, DC
36. D.R. Jasinski, J.S. Pevnick, and J.D. Griffith Human pharmacology and abuse potential of the analgesic buprenorphine: a potential agent for treating narcotic addiction Arch Gen Psychiatry 35 1978 501 516
37. M. Jofre-Bonet, J.L. Sindelar, I.L. Petrakis, C. Nich, T. Frankforter, and B.J. Rounsaville Cost effectiveness of disulfiram: treating cocaine use in methadone-maintained patients J Subst Abuse Treat 26 2004 225 232
38. R.E. Johnson, M.A. Chutuape, E.C. Strain, S.L. Walsh, M.L. Stitzer, and G.E. Bigelow A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence N Engl J Med 343 2000 1290 1297
39. J. Kakko, K.D. Svanborg, M.J. Kreek, and M. Heilig 1-Year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: a randomised, placebo-controlled trial Lancet 361 2003 662 668 (comment)
40. R.C. Kessler, K.A. McGonagle, S. Zhao, C.B. Nelson, M. Hughes, and S. Eshleman Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the united states. Results from the national comorbidity survey Arch Gen Psychiatry 51 1994 8 19
41. C. Laine, W.W. Hauck, M.N. Gourevitch, J. Rothman, A. Cohen, and B.J. Turner Regular outpatient medical and drug abuse care and subsequent hospitalization of persons who use illicit drugs JAMA 285 2001 2355 2362
42. C.S. Lieber Hepatic and other medical disorders of alcoholism: from pathogenesis to treatment J Stud Alcohol 59 1998 9 25
43. R.M. Makower, A.G. Pennycook, and C. Moulton Intravenous drug abusers attending an inner city accident and emergency department Arch Emerg Med 9 1992 32 39
44. T.L. Mark, G.E. Woody, T. Juday, and H.D. Kleber The economic costs of heroin addiction in the United States Drug Alcohol Depend 61 2001 195 206
45. T.L. Mark, H.R. Kranzler, X. Song, P. Bransberger, V.H. Poole, and S. Crosse Physicians' opinions about medications to treat alcoholism Addiction 98 2003 617 626
46. D. McCarty, T. Rieckmann, C. Green, S. Gallon, and J. Knudsen Training rural practitioners to use buprenorphine: using the change book to facilitate technology transfer J Subst Abuse Treat 26 2005 203 208
47. K.E. McCollister, and M.T. French The relative contribution of outcome domains in the total economic benefit of addiction interventions: a review of first findings (see comment) Addiction 98 2003 1647 1659
48. J.M. McGinnis, and W.H. Foege Mortality and morbidity attributable to use of addictive substances in the united states Proc Assoc Am Physicians 111 1999 109 118
49. A.T. McLellan, D.C. Lewis, C.P. O'Brien, and H.D. Kleber Drug dependence, a chronic medical illness: implications for treatment, insurance, and outcomes evaluation JAMA 284 2000 1689 1695
50. N.S. Miller, L.M. Sheppard, C.C. Colenda, and J. Magen Why physicians are unprepared to treat patients who have alcohol- and drug-related disorders Acad Med 76 2001 410 418
51. D.F. Musto The American Disease 1987 Oxford University Press, Inc. New York, NY
52. National Consensus Development Panel on Effective Medical Treatment of Opiate Addiction Effective medical treatment of opiate addiction. National Consensus Development Panel on effective medical treatment of opiate addiction (see comments) JAMA 280 1998 1936 1943
53. D.N. Nurco, J.C. Ball, J.W. Shaffer, and T.E. Hanlon The criminality of narcotic addicts J Nerv Ment Dis 173 1985 94 102
54. N. O'Connor, P.I. Dargan, and A.L. Jones Hepatocellular damage from non-steroidal anti-inflammatory drugs QJM 96 2003 787 791
55. Office of Applied Studies Overview of Findings from the 2003 National Survey on Drug Use and Health 2004 Substance Abuse and Mental Health Services Administration Rockville, MD
56. Office of Applied Studies Mortality Data from the Drug Abuse Warning Network, 2002 2004 Substance Abuse and Mental Health Services Administration Rockville, MD
57. S. Parthasarathy, C. Weisner, T.W. Hu, and C. Moore Association of outpatient alcohol and drug treatment with health care utilization and cost: revisiting the offset hypothesis J Stud Alcohol 62 2001 89 97
58. D.A. Regier, M.E. Farmer, D.S. Rae, B.Z. Locke, S.J. Keith, and L.L. Judd Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study JAMA 264 1990 2511 2518
59. E.B. Ritson Alcohol, drugs and stigma Int J Clin Pract 53 1999 549 551
60. E.M. Rogers Diffusion of Innovations 1995 Free Press New York, NY
61. P.M. Roman, and J.A. Johnson Adoption and implementation of new technologies in substance abuse treatment J Subst Abuse Treat 22 2002 211 218
62. M.D. Roth, A. Arora, S.H. Barsky, E.C. Kleerup, M. Simmons, and D.P. Tashkin Airway inflammation in young marijuana and tobacco smokers Am J Respir Crit Care Med 157 1998 928 937
63. B.J. Rounsaville, S.F. Anton, K. Carroll, D. Budde, B.A. Prusoff, and F. Gawin Psychiatric diagnoses of treatment-seeking cocaine abusers Arch Gen Psychiatry 48 1991 43 51
64. A.J. Saxon, and D.A. Calsyn Effects of psychiatric care for dual diagnosis patients treated in a drug dependence clin Am J Drug Alcohol Abuse 21 1995 303 313
65. R.P. Schwartz, R.K. Brooner, I.D. Montoya, M. Currens, and M. Hayes A 12-year follow-up of a methadone medical maintenance program Am J Addict 8 1999 293 299
66. D.D. Simpson A conceptual framework for transferring research to practice J Subst Abuse Treat 22 2002 171 182
67. S.B. Soumerai, T.J. McLaughlin, and J. Avorn Improving drug prescribing in primary care: a critical analysis of the experimental literature Milbank Q 67 1989 268 317
68. R. Sturm, W. Zhang, and M. Schoenbaum How expensive are unlimited substance abuse benefits under managed care? J Behav Health Serv Res 26 1999 203 210
69. L.E. Sullivan, and D.A. Fiellin Hepatitis C and HIV infections: implications for clinical care in injection drug users Am J Addict 13 2004 1 20
70. R.M. Swift Drug therapy for alcohol dependence N Engl J Med 340 1999 1482 1490
71. D.P. Tashkin, M.E. Khalsa, D. Gorelick, P. Chang, M.S. Simmons, and A.H. Coulson Pulmonary status of habitual cocaine smokers Am Rev Respir Dis 145 1992 92 100
72. C.P. Thomas, and D. McCarty Adoption of drug abuse treatment technology in specialty and primary care settings H.J. Harwood T.G. Myers New Treatments for Addiction: Behavioral, Ethical, Legal, and Social Questions 2004 The National Academies Press Washington, DC 140 172
73. C.P. Thomas, S.S. Wallack, S. Lee, D. McCarty, and R. Swift Research to practice: adoption of naltrexone in alcoholism treatment J Subst Abuse Treat 24 2003 1 11
74. M.A. Thomson O'Brien, A.D. Oxman, R.B. Haynes, D.A. Davis, N. Freemantle, and E.L. Harvey Local opinion leaders: effects on professional practice and health care outcomes Cochrane Database Syst Rev 2000 2
75. S.L. Walsh, H.L. June, K.J. Schuh, K.L. Preston, G.E. Bigelow, and M.L. Stitzer Effects of buprenorphine and methadone in methadone-maintained subjects Psychopharmacology 119 1995 268 276
76. T.M. Wickizer, K. Campbell, A. Krupski, and K. Stark Employment outcomes among AFDC recipients treated for substance abuse in Washington state Milbank Q 78 2000 585 608
77. D.A. Zanis, and G.E. Woody One-year mortality rates following methadone treatment discharge Drug Alcohol Depend 52 1998 257 260